Article

Schwind eye-tech premieres excimer laser

Schwind eye-tech-solutions premiered its new excimer laser (Amaris) at the annual meeting of the European Society of Cataract and Refractive Surgeons in Stockholm, Sweden.

Kleinostheim, Germany-Schwind eye-tech-solutions premiered its new excimer laser (Amaris) at the annual meeting of the European Society of Cataract and Refractive Surgeons in Stockholm, Sweden.

Among its features, the laser offers a pulse frequency of 500 Hz, two automatically adapted fluence levels for ablation control, and what the company says is the fastest eye tracker on the market-with a response time of less than 3 milliseconds-compensating every movement of the eye up to the fifth dimension. In addition, with online pachymetry, the laser continuously measures corneal thickness during the treatment, allowing the surgeon to decide at any time how best to proceed with a refractive correction.

One-month results of the first international multicenter LASIK study with the laser are encouraging regarding visual acuity (VA), predictability, and variance, according to the company. The study involved 389 myopic eyes in patients aged 18 to 60 years. Some of the patients also had astigmatism.

Also after 1 month, postoperative uncorrected VA of 20/20 or better was achieved in more than 92% of treated patients. No single patient eye had a VA of less than 20/32. In 99%, UCVA of 20/25 or better was achieved, and VA of 20/16 or better was achieved in more than 32% of study participants.

No trend toward overcorrection or undercorrection was detected after 1 month. All results were obtained without the use of individual nomograms.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.